Results 81 to 90 of about 2,492 (186)

Restoring well-being: quality of life improvements following dolutegravir-based therapy after antiretroviral failure. [PDF]

Braz J Infect Dis
Lins-Kusterer L, Brites C, de Lacerda MVG, Page K, Bahia F, Luz E, Ramalho A, Wagner S, Arriaga MB, CODE research group collaborators.   +9 more
europepmc   +1 more source

Gold(I)-Catalyzed Synthesis of 4H‑Benzo[d][1,3]oxazines and Biological Evaluation of Activity in Breast Cancer Cells

ACS Omega, 2022
Luis A. Segura-Quezada, Karina R. Torres-Carbajal, Narendra Mali, Dipak B. Patil, Mauricio Luna-Chagolla, Rafael Ortiz-Alvarado, Melissa Tapia-Juárez, Ixamail Fraire-Soto, Jorge Gustavo Araujo-Huitrado, Angelica Judith Granados-López, Rosalinda Gutiérrez-Hernández, Claudia Araceli Reyes-Estrada, Yamilé López-Hernández, Jesús Adrián López, Luis Chacón-García, César R. Solorio-Alvarado   +15 more
doaj   +1 more source

A fluorescent counterstaining technique to differentiate microplastics from chitin using Nile red and calcofluor white in edible grasshoppers. [PDF]

Environ Monit Assess
Tapia-Bahena E, Contreras-Jiménez G, Tapia-Maruri D, Córdoba-Aguilar A.   +3 more
europepmc   +1 more source

Efficacy and metabolic outcomes of switching from an INSTI-based triple-drug regimen to dolutegravir/lamivudine in treatment-experienced HIV-1-infected patients: a 48-week real-world study. [PDF]

Ann Med
Zhang W, Li Q, Deng C, Yuan J.
europepmc   +1 more source

HIV low-level viraemia: considerations for prevention and treatment in an era of highly effective and durable antiretroviral therapy regimens. [PDF]

J Int AIDS Soc
Vojnov L, Bekker LG, Cohen MS, Jahn A, Havlir D, Boeras D, Ford N, Kumarasamy N, Broyles LN.   +8 more
europepmc   +1 more source

Recent advances in the transformation reactions of the Betti base derivatives. [PDF]

RSC Adv
Olyaei A, Sadeghpour M.
europepmc   +1 more source

Adverse Drug Reactions Related to Isoniazid Preventive Therapy Among Persons Living With HIV on Dolutegravir-Based Regimens in Uganda Between July 2019 and March 2020. [PDF]

J Acquir Immune Defic Syndr
Nalugga EA, Musaazi J, Manabe YC, Kalema N, Castelnuovo B, Odongpiny EAL, Nabukenya-Mudiope MG, Kavuma P, Kigozi J, Muganzi A, Alamo S, Namayanja G, Lukoye D, Ssempiira J, Zawedde-Muyanja S.   +14 more
europepmc   +1 more source

Dolutegravir concentrations in children receiving 3-month weekly isoniazid and rifapentine (3HP) for tuberculosis prevention. [PDF]

Microbiol Spectr
Madzime RJ, van der Laan L, du Toit S, Barnabas S, Courtney I, Brown NE, Savic R, Solans BP, Dixon MG, Tsirizani L, Denti P, Boyd R, Hesseling AC, TBTC Study 35 team.   +13 more
europepmc   +1 more source

Iodine-Catalyzed Functionalization of Primary Aliphatic Amines to Oxazoles, 1,4-Oxazines, and Oxazinones

ACS Omega, 2019
Sudipto Debnath, Tuluma Das, Subrata Gayen, Tapas Ghosh, Dilip K. Maiti   +4 more
doaj   +1 more source

Two cases of possible transmitted HIV drug resistance to all currently available integrase inhibitors, the Netherlands, 2025. [PDF]

Euro Surveill
van Kampen J, Voermans J, Soochit W, Mesplède T, van de Laar T, van der Reijden W, Burger D, Shalev N, van Sighem A, Bezemer D, Jurriaans S, van der Vaart T, de Jong H, van der Valk M.   +13 more
europepmc   +1 more source